What to Expect From a New Obstructive Hypertrophic Cardiomyopathy Treatment Plan

What to Expect From a New Obstructive Hypertrophic Cardiomyopathy Treatment Plan

What to Expect From a New Obstructive Hypertrophic Cardiomyopathy Treatment Plan
Alamy

Starting a new medication for obstructive hypertrophic cardiomyopathy (oHCM) often means more appointments and testing. But that extra monitoring exists for a reason: It helps your care team find the right dose and ensures your heart is responding safely.

This is especially the case if you’re starting a cardiac myosin inhibitor, which eases the strength of your heart’s contractions and reduces the blockage caused by the thickened heart muscle.

“These medications are a little bit more nuanced and require a little bit more frequent follow-up,” says Jessica Lauren Atkins, MD, a cardiologist specializing in hypertrophic cardiomyopathy at Medical University of South Carolina Health in Charleston.

Once you know what’s coming, though, the schedule tends to feel a lot less daunting.

Your Pretreatment Checklist

Before you start a medication, your care team will likely order an echocardiogram to determine how well your heart is currently functioning. An echocardiogram is an ultrasound for your heart: It evaluates heart muscle contraction, tracks your blood flow, checks your valves, and measures muscle thickness.

“We can look at the heart squeeze. We can evaluate all the valves. And then we can also identify if there’s any level of obstruction or abnormal muscle thickening that’s blocking the blood flow moving through the heart,” says Dr. Atkins.

Your doctor may also want to schedule an EKG (electrocardiogram) to check your heart’s electrical activity or send you home with a Holter monitor to track your heart rhythm over the course of a few days, she says.

If you’re a candidate for a cardiac myosin inhibitor (aficamten or mavacamten), a treatment used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy, your doctor will check your left ventricular ejection fraction to see if it’s at 55 percent or higher. If not, treatment can’t begin.

Your doctor will also review a list of all the drugs and supplements you take. Several heart-rhythm and cardiac medications aren’t recommended alongside myosin inhibitors, because combining them raises the risk of your heart pumping too weakly. Some common drugs, including antifungal medication and heartburn medication, and herbal supplements can also change how your body processes the pill.

The Initiation and Titration Phase

The medication dose may need to be adjusted, or titrated, over time. Your care team will track symptoms and your echocardiogram results to decide whether the current dose is working well or needs a change.

If you’re taking mavacamten, you’ll need an echocardiogram at weeks 4, 8, and 12 to measure your left ventricular ejection fraction and heart pressure.

If you’re taking aficamten, you’ll need an echocardiogram every two to eight weeks after starting the pill or changing the dose. The schedule follows dosage changes, not a fixed calendar.

Overall, Atkins says people starting these medications are “often coming in about every month or so for the first few months of therapy” until test results stabilize and breathing improves.

At these visits, expect a symptom check and another echocardiogram. Your care team will be monitoring your heart to see if it’s less obstructed and strong enough that it’s pumping effectively.

Both medications require enrollment in a risk evaluation and mitigation strategy program, because relaxing the heart too much can trigger heart failure. If your left ventricular ejection fraction drops below 50 percent while on the medication, your doctor will pause or adjust the dose.

Long-Term oHCM Maintenance and Safety

Once the dose is stable, your appointments will ease up, requiring follow-ups every three to six months, says Atkins.

Echocardiograms continue long term — roughly every six months for both drugs. The U.S. Food and Drug Administration recently updated mavacamten’s label to allow for echocardiograms every six months after you’re stable, replacing the older 12-week requirement. Your doctor may adjust the timing based on your health.

The testing continues because myosin inhibitors can lower your heart’s pumping strength over time. Routine echocardiograms catch that shift early. If your left ventricular ejection fraction stays below 50 percent, current guidelines call for stopping the medication or decreasing the dose, depending on which medication you’re taking and what your ejection fraction is.

Symptoms matter just as much as lab results, so watch for any change in what you’re able to do, says Atkins. “Anything that is not getting better is something that we should pay attention to,” she says. And call your care team right away if you notice new shortness of breath, lightheadedness, fainting, or dizziness or a racing heartbeat.

Practical Tips for Managing Your oHCM Monitoring Schedule

The following strategies can make your medical schedule easier to manage:

  • Batch your visits. Ask if your echocardiogram and cardiology check-in can happen the same day.
  • Set reminders. Put echocardiogram dates, prescription refills, and clinic visits on your phone calendar.
  • Give your workplace a heads-up. Let your employer know early that you’ll need some flexibility over the next few months.
  • Keep a symptom log. Jot down what you do each day and which tasks feel as if they’re getting harder to do, says Atkins.

And don’t be afraid to ask questions. Before starting any new medication, Atkins says she and her team walk her patients through “the benefits, the risks, side effects, and the follow-up that’s necessary.”

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Ostrominski JW et al. Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy: JACC: Heart Failure State-of-the-Art Review. Journal of the American College of Cardiology. July 1, 2023.
  2. Ommen SR et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. June 2024.
  3. CAMZYOS (mavacamten) Capsules for Oral Use Prescribing Information. U.S. Food and Drug Administration. April 2025.
  4. MYQORZO (aficamten) Tablets, for Oral Use Prescribing Information. U.S. Food and Drug Administration. December 2025.
Cheng-Han Chen

Cheng-Han Chen, MD, PhD, FACC, FSCAI

Medical Reviewer

Cheng-Han Chen, MD, PhD, is the medical director of the structural heart program at MemorialCare Saddleback Medical Center in Laguna Hills, California, and director of structural a...

Susan Jara

Author

Susan Jara is a health communications strategist and writer with more than 15 years of experience transforming complex medical information into clear, accurate, and engaging conten...